Inflammatory mechanisms in patients with chronic obstructive pulmonary disease

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 1, 2016, Pages 16-27

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

autoantibody; chemokine; cytokine; Inflammation; macrophage; neutrophil; nuclear factor B; oxidative stress

Indexed keywords

ANTIINFLAMMATORY AGENT; AUTOANTIBODY; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CANAKINUMAB; CHEMOKINE; CIGARETTE SMOKE; CORTICOSTEROID; CYTOKINE; FREE RADICAL; GELATINASE B; GROWTH FACTOR; HISTONE DEACETYLASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; LIPID; PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; STEROID; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; AUTACOID;

ADAPTIVE IMMUNITY; AGING; AIRWAY; BIOLOGICAL THERAPY; BREATHING; BRONCHUS BIOPSY; CARDIOVASCULAR DISEASE; CELL AGING; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORTICOSTEROID THERAPY; DENDRITIC CELL; DISEASE SEVERITY; DNA DAMAGE; ENZYME INACTIVATION; EOSINOPHIL; EPITHELIUM CELL; EXHALATION; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; LUNG; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG PARENCHYMA; LYMPHOCYTE; MACROPHAGE; MEDIATOR; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; STEROID THERAPY; T LYMPHOCYTE; TREATMENT RESPONSE; ANIMAL; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; RISK FACTOR;

ANIMALS; CYTOKINES; HUMANS; INFLAMMASOMES; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; OXIDATIVE STRESS; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; RISK FACTORS;

EID: 84990960707     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.05.011     Document Type: Review

References (118)

1. 1 Barnes, P.J., Burney, P.G.J., Silverman, E.K., Celli, B.R., Vestbo, J., Wedzicha, J.A., et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers, 1, 2015, 15076.
2. 2 Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
3. 3 Castaldi, P.J., Dy, J., Ross, J., Chang, Y., Washko, G.R., Curran-Everett, D., et al. Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax 69 (2014), 415–422.
4. 4 Burgel, P.R., Paillasseur, J.L., Caillaud, D., Tillie-Leblond, I., Chanez, P., Escamilla, R., et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 36 (2010), 531–539.
5. 5 Barnes, P.J., Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 35 (2014), 71–86.
6. 6 Lange, P., Celli, B., Agusti, A., Boje Jensen, G., Divo, M., Faner, R., et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 373 (2015), 111–122.
7. 7 Iyer, N., Brashier, B., Madas, S., Londhe, J., Salvi, S., Barnes, P.J., Physiological and inflammatory phenotypic comparisons between non-smoking and smoking COPD. Eur Resp J, 42(Suppl 57), 2013, 3042.
8. 8 Barnes, P.J., New anti-inflammatory treatments for chronic obstructive pulmonary disease. Nat Rev Drug Discov 12 (2013), 543–559.
9. 9 Hogg, J.C., Chu, F., Utokaparch, S., Woods, R., Elliott, W.M., Buzatu, L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 (2004), 2645–2653.
10. 10 McDonough, J.E., Yuan, R., Suzuki, M., Seyednejad, N., Elliott, W.M., Sanchez, P.G., et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 365 (2011), 1567–1575.
11. 11 Galban, C.J., Han, M.K., Boes, J.L., Chughtai, K.A., Meyer, C.R., Johnson, T.D., et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med 18 (2012), 1711–1715.
12. 12 Ofir, D., Laveneziana, P., Webb, K.A., Lam, Y.M., O'Donnell, D.E., Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177 (2008), 622–629.
13. 13 O'Donnell, D.E., Laveneziana, P., Webb, K., Neder, J.A., Chronic obstructive pulmonary disease: clinical integrative physiology. Clin Chest Med 35 (2014), 51–69.
14. 14 Perez-Padilla, R., Schilmann, A., Riojas-Rodriguez, H., Respiratory health effects of indoor air pollution. Int J Tuberc Lung Dis 14 (2010), 1079–1086.
15. 15 Joshi, M., Joshi, A., Bartter, T., Marijuana and lung diseases. Curr Opin Pulm Med 20 (2014), 173–179.
16. 16 Barnes, P.J., Immunology of asthma and chronic obstructive pulmonary disease. Nat Immunol Rev 8 (2008), 183–192.
17. 17 Brusselle, G.G., Joos, G.F., Bracke, K.R., New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378 (2011), 1015–1026.
18. 18 Givi, M.E., Redegeld, F.A., Folkerts, G., Mortaz, E., Dendritic cells in pathogenesis of COPD. Curr Pharm Des 18 (2012), 2329–2335.
19. 19 Gamble, E., Grootendorst, D.C., Hattotuwa, K., O'Shaughnessy, T., Ram, F.S., Qiu, Y., et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J 30 (2007), 467–471.
20. 20 Gao, W., Li, L., Wang, Y., Zhang, S., Adcock, I.M., Barnes, P.J., et al. Bronchial epithelial cells: The key effector cells in the pathogenesis of chronic obstructive pulmonary disease?. Respirology 20 (2015), 722–729.
21. 21 Kanazawa, H., Tochino, Y., Asai, K., Hirata, K., Simultaneous assessment of hepatocyte growth factor and vascular endothelial growth factor in epithelial lining fluid from patients with COPD. Chest 146 (2014), 1159–1165.
22. 22 de Boer, W.I., Hau, C.M., van Schadewijk, A., Stolk, J., van Krieken, J.H., Hiemstra, P.S., Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 125 (2006), 184–192.
23. 23 Perl, A.K., Riethmacher, D., Whitsett, J.A., Conditional depletion of airway progenitor cells induces peribronchiolar fibrosis. Am J Respir Crit Care Med 183 (2011), 511–521.
24. 24 Gamez, A.S., Gras, D., Petit, A., Knabe, L., Molinari, N., Vachier, I., et al. Supplementing defect in Club Cell Secretory Protein attenuates airway inflammation in COPD. Chest 147 (2015), 1467–1476.
25. 25 Burgel, P.R., Nadel, J.A., Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 59 (2004), 992–996.
26. 26 Shao, M.X., Nakanaga, T., Nadel, J.A., Cigarette smoke Induces MUC5AC mucin overproduction via tumor necrosis factor-a converting enzyme in human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol 287 (2004), L420–L427.
27. 27 Takezawa, K., Ogawa, T., Shimizu, S., Shimizu, T., Epidermal growth factor receptor inhibitor AG1478 inhibits mucus hypersecretion in airway epithelium. Am J Rhinol Allergy 30 (2016), 1–6.
28. 28 Woodruff, P.G., Wolff, M., Hohlfeld, J.M., Krug, N., Dransfield, M.T., Sutherland, E.R., et al. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181 (2010), 438–445.
29. 29 Barnes, P.J., Macrophages as orchestrators of COPD. COPD 1 (2004), 59–70.
30. 30 Russell, R.E., Thorley, A., Culpitt, S.V., Dodd, S., Donnelly, L.E., Demattos, C., et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 283 (2002), L867–L873.
31. 31 Gordon, S., Pluddemann, A., Tissue macrophage heterogeneity: issues and prospects. Semin Immunopathol 35 (2013), 533–540.
32. 32 Chana, K.K., Fenwick, P.S., Nicholson, A.G., Barnes, P.J., Donnelly, L.E., Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 133 (2014), 207–216.
33. 33 Caramori, G., Romagnoli, M., Casolari, P., Bellettato, C., Casoni, G., Boschetto, P., et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 58 (2003), 348–351.
34. 34 Traves, S.L., Culpitt, S., Russell, R.E.K., Barnes, P.J., Donnelly, L.E., Elevated levels of the chemokines GRO-a and MCP-1 in sputum samples from COPD patients. Thorax 57 (2002), 590–595.
35. 35 Traves, S.L., Smith, S.J., Barnes, P.J., Donnelly, L.E., Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 76 (2004), 441–450.
36. 36 Grumelli, S., Corry, D.B., Song, L.-X., Song, L., Green, L., Huh, J., et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 1 (2004), 75–83.
37. 37 Culpitt, S.V., Rogers, D.F., Shah, P., de Matos, C., Russell, R.E., Donnelly, L.E., et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167 (2003), 24–31.
38. 38 Barnes, P.J., Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 131 (2013), 636–645.
39. 39 Barnes, P.J., Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 71 (2009), 451–464.
40. 40 Taylor, A.E., Finney-Hayward, T.K., Quint, J.K., Thomas, C.M., Tudhope, S.J., Wedzicha, J.A., et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J 35 (2010), 1039–1047.
41. 41 Hodge, S., Hodge, G., Scicchitano, R., Reynolds, P.N., Holmes, M., Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 81 (2003), 289–296.
42. 42 Donnelly, L.E., Barnes, P.J., Defective phagocytosis in airways disease. Chest 141 (2012), 1055–1062.
43. 43 Singh, R., Mackay, A.J., Patel, A., Garcha, D.S., Kowlessar, B.S., Brill, S.E., et al. Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res, 15, 2014, 114.
44. 44 Di Stefano, A., Maestrelli, P., Roggeri, A., Turato, G., Calabro, S., Potena, A., et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 149 (1994), 803–810.
45. 45 Keatings, V.M., Barnes, P.J., Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma and normal subjects. Am J Respir Crit Care Med 155 (1997), 449–453.
46. 46 Fahy, J.V., Dickey, B.F., Airway mucus function and dysfunction. N Engl J Med 363 (2010), 2233–2247.
47. 47 Biernacki, W.A., Kharitonov, S.A., Barnes, P.J., Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 58 (2003), 294–298.
48. 48 Sapey, E., Stockley, J.A., Greenwood, H., Ahmad, A., Bayley, D., Lord, J.M., et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 183 (2011), 1176–1186.
49. 49 Postma, D.S., Rabe, K.F., The asthma-COPD overlap syndrome. N Engl J Med 373 (2015), 1241–1249.
50. 50 Bateman, E.D., Reddel, H.K., van Zyl-Smit, R.N., Agusti, A., The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?. Lancet Respir Med 3 (2015), 719–728.
51. 51 Barnes, P.J., Asthma-COPD Overlap. Chest 149 (2016), 7–8.
52. 52 Cosio, B.G., Soriano, J.B., Lopez-Campos, J.L., Calle-Rubio, M., Soler-Cataluna, J.J., de-Torres, J.P., et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest 149 (2016), 45–52.
53. 53 Scanlon, S.T., McKenzie, A.N., Type 2 innate lymphoid cells: new players in asthma and allergy. Curr Opin Immunol 24 (2012), 707–712.
54. 54 De Grove, K.C., Provoost, S., Verhamme, F.M., Bracke, K.R., Joos, G.F., Maes, T., et al. Characterization and quantification of innate lymphoid cell subsets in human lung. PLoS One, 11, 2016, e0145961.
55. 55 Byers, D.E., Alexander-Brett, J., Patel, A.C., Agapov, E., Dang-Vu, G., Jin, X., et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123 (2013), 3967–3982.
56. 56 Silver, J.S., Kearley, J., Copenhaver, A.M., Sanden, C., Mori, M., Yu, L., et al. Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat Immunol 17 (2016), 626–635.
57. 57 Bafadhel, M., Saha, S., Siva, R., McCormick, M., Monteiro, W., Rugman, P., et al. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration 78 (2009), 256–262.
58. 58 Eltboli, O., Mistry, V., Barker, B., Brightling, C.E., Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology 20 (2015), 667–670.
59. 59 Pascoe, S., Locantore, N., Dransfield, M.T., Barnes, N.C., Pavord, I.D., Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3 (2015), 435–442.
60. 60 Pavord, I.D., Lettis, S., Locantore, N., Pascoe, S., Jones, P.W., Wedzicha, J.A., et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 71 (2016), 118–125.
61. 61 Zhu, J., Qiu, Y.S., Majumdar, S., Gamble, E., Matin, D., Turato, G., et al. Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 164 (2001), 109–116.
62. 62 Saetta, M., Di Stefano, A., Turato, G., Facchini, F.M., Corbino, L., Mapp, C.E., et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998), 822–826.
63. 63 Di Stefano, A., Caramori, G., Capelli, A., Gnemmi, I., Ricciardolo, F., Oates, T., et al. STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J 24 (2004), 78–85.
64. 64 Di Stefano, A., Caramori, G., Gnemmi, I., Contoli, M., Vicari, C., Capelli, A., et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol 157 (2009), 316–324.
65. 65 Pridgeon, C., Bugeon, L., Donnelly, L., Straschil, U., Tudhope, S.J., Fenwick, P., et al. Regulation of IL-17 in chronic inflammation in the human lung. Clin Sci (Lond) 120 (2011), 515–524.
66. 66 Costa, C., Rufino, R., Traves, S.L., Lapa E Silva, J.R., Barnes, P.J., Donnelly, L.E., CXCR3 and CCR5 chemokines in the induced sputum from patients with COPD. Chest 133 (2008), 26–33.
67. 67 Saetta, M., Mariani, M., Panina-Bordignon, P., Turato, G., Buonsanti, C., Baraldo, S., et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165 (2002), 1404–1409.
68. 68 Artis, D., Spits, H., The biology of innate lymphoid cells. Nature 517 (2015), 293–301.
69. 69 Kirkham, P.A., Caramori, G., Casolari, P., Papi, A., Edwards, M., Shamji, B., et al. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of COPD. Am J Respir Crit Care Med 184 (2011), 796–802.
70. 70 Karayama, M., Inui, N., Suda, T., Nakamura, Y., Nakamura, H., Chida, K., Antiendothelial cell antibodies in patients with COPD. Chest 138 (2010), 1303–1308.
71. 71 Klareskog, L., Catrina, A.I., Autoimmunity: lungs and citrullination. Nat Rev Rheumatol 11 (2015), 261–262.
72. 72 Majo, J., Ghezzo, H., Cosio, M.G., Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 17 (2001), 946–953.
73. 73 Lambers, C., Hacker, S., Posch, M., Hoetzenecker, K., Pollreisz, A., Lichtenauer, M., et al. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 155 (2009), 466–475.
74. 74 Hodge, G., Mukaro, V., Reynolds, P.N., Hodge, S., Role of increased CD8/CD28(null) T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease. Clin Exp Immunol 166 (2011), 94–102.
75. 75 Hodge, G., Jersmann, H., Tran, H.B., Roscioli, E., Holmes, M., Reynolds, P.N., et al. Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes. Respir Res, 16, 2015, 130.
76. 76 Seys, L.J., Verhamme, F.M., Schinwald, A., Hammad, H., Cunoosamy, D.M., Bantsimba-Malanda, C., et al. Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 192 (2015), 706–718.
77. 77 Van Pottelberge, G.R., Bracke, K.R., Demedts, I.K., De Rijck, K., Reinartz, S.M., van Drunen, C.M., et al. Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD. Respir Res, 11, 2010, 35.
78. 78 Freeman, C.M., Martinez, F.J., Han, M.K., Ames, T.M., Chensue, S.W., Todt, J.C., et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180 (2009), 1179–1188.
79. 79 Vassallo, R., Walters, P.R., Lamont, J., Kottom, T.J., Yi, E.S., Limper, A.H., Cigarette smoke promotes dendritic cell accumulation in COPD; a Lung Tissue Research Consortium study. Respir Res, 11, 2010, 45.
80. 80 Barnes, P.J., Mediators of chronic obstructive pulmonary disease. Pharm Rev 56 (2004), 515–548.
81. 81 Montuschi, P., Kharitonov, S.A., Ciabattoni, G., Barnes, P.J., Exhaled leukotrienes and prostaglandins in COPD. Thorax 58 (2003), 585–588.
82. 82 Beeh, K.M., Kornmann, O., Buhl, R., Culpitt, S.V., Giembycz, M.A., Barnes, P.J., Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 123 (2003), 1240–1247.
83. 83 Barnes, P.J., The cytokine network in COPD. Am J Respir Cell Mol Biol 41 (2009), 631–638.
84. 84 Rennard, S.I., Fogarty, C., Kelsen, S., Long, W., Ramsdell, J., Allison, J., et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007), 926–934.
85. 85 Jo, E.K., Kim, J.K., Shin, D.M., Sasakawa, C., Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 13 (2016), 148–159.
86. 86 Kim, R.Y., Pinkerton, J.W., Gibson, P.G., Cooper, M.A., Horvat, J.C., Hansbro, P.M., Inflammasomes in COPD and neutrophilic asthma. Thorax 70 (2015), 1199–1201.
87. 87 Franklin, B.S., Bossaller, L., De Nardo, D., Ratter, J.M., Stutz, A., Engels, G., et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol 15 (2014), 727–737.
88. 88 Rogliani, P., Calzetta, L., Ora, J., Matera, M.G., Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 31 (2015), 15–27.
89. 89 Doe, C., Bafadhel, M., Siddiqui, S., Desai, D., Mistry, V., Rugman, P., et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 138 (2010), 1140–1147.
90. 90 Donnelly, L.E., Barnes, P.J., Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 27 (2006), 546–553.
91. 91 Costa, C., Traves, S.L., Tudhope, S.J., Fenwick, P.S., Belchamber, K.B., Russell, R.E., et al. Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. Eur Respir J, 2016 [Epub ahead of print].
92. 92 Gaggar, A., Jackson, P.L., Noerager, B.D., O'Reilly, P.J., McQuaid, D.B., Rowe, S.M., et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 180 (2008), 5662–5669.
93. 93 Xu, X., Jackson, P.L., Tanner, S., Hardison, M.T., Abdul, R.M., Blalock, J.E., et al. A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS One, 6, 2011, e15781.
94. 94 Takeyama, K., Fahy, J.V., Nadel, J.A., Relationship of epidermal growth factor receptors to goblet cell production in human bronchi. Am J Respir Crit Care Med 163 (2001), 511–516.
95. 95 Kirkham, P.A., Barnes, P.J., Oxidative stress in COPD. Chest 144 (2013), 266–273.
96. 96 Montuschi, P., Barnes, P.J., Roberts, L.J., Isoprostanes: markers and mediators of oxidative stress. FASEB J 18 (2004), 1791–1800.
97. 97 Osoata, G.O., Hanazawa, T., Brindicci, C., Ito, M., Barnes, P.J., Kharitonov, S., et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest 135 (2009), 1513–1520.
98. 98 Brindicci, C., Kharitonov, S.A., Ito, M., Elliott, M.W., Hogg, J.C., Barnes, P.J., et al. Nitric oxide synthase isoenzyme expression and activity in peripheral lungs of COPD patients. Am J Respir Crit Care Med 181 (2010), 21–30.
99. 99 Malhotra, D., Thimmulappa, R., Navas-Acien, A., Sandford, A., Elliott, M., Singh, A., et al. Decline in NRF2 regulated antioxidants in COPD lungs due to loss of its positive regulator DJ-1. Am J Respir Crit Care Med 178 (2008), 592–604.
100. 100 Mercado, N., Thimmulappa, R., Thomas, C.M., Fenwick, P.S., Chana, K.K., Donnelly, L.E., et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun 406 (2011), 292–298.
101. 101 Tomita, K., Barnes, P.J., Adcock, I.M., The effect of oxidative stress on histone acetylation and IL-8 release. Biochem Biophys Res Comm 301 (2003), 572–577.
102. 102 Nakamaru, Y., Vuppusetty, C., Wada, H., Milne, J.C., Ito, M., Rossios, C., et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 23 (2009), 2810–2819.
103. 103 Mercado, N., Ito, K., Barnes, P.J., Accelerated ageing in chronic obstructive pulmonary disease: new concepts. Thorax 70 (2015), 482–489.
104. 104 Caramori, G., Adcock, I.M., Casolari, P., Ito, K., Jazrawi, E., Tsaprouni, L., et al. Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax 66 (2011), 521–527.
105. 105 Gan, W.Q., Man, S.F., Senthilselvan, A., Sin, D.D., Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 (2004), 574–580.
106. 106 Agusti, A., Edwards, L.D., Rennard, S.I., Macnee, W., Tal-Singer, R., Miller, B.E., et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One, 7, 2012, e37483.
107. 107 Thomsen, M., Dahl, M., Lange, P., Vestbo, J., Nordestgaard, B.G., Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186 (2012), 982–988.
108. 108 Hurst, J.R., Donaldson, G.C., Perea, W.R., Wilkinson, T.M., Bilello, J.A., Hagan, G.W., et al. Utility of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174 (2006), 867–874.
109. 109 Serhan, C.N., Pro-resolving lipid mediators are leads for resolution physiology. Nature 510 (2014), 92–101.
110. 110 Serhan, C.N., Yang, R., Martinod, K., Kasuga, K., Pillai, P.S., Porter, T.F., et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 206 (2009), 15–23.
111. 111 Barnes, P.J., Mechanisms of development of multimorbidity in the elderly. Eur Respir J 45 (2015), 790–806.
112. 112 Mitani, A., Ito, K., Vuppusetty, C., Barnes, P.J., Mercado, N., Inhibition of mTOR restores corticosteroid sensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 193 (2015), 143–153.
113. 113 Tsuji, T., Aoshiba, K., Nagai, A., Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 174 (2006), 886–893.
114. 114 Kumar, M., Seeger, W., Voswinckel, R., Senescence-associated secretory phenotype and its possible role in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 51 (2014), 323–333.
115. 115 de Boer, W.I., van Schadewijk, A., Sont, J.K., Sharma, H.S., Stolk, J., Hiemstra, P.S., et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158 (1998), 1951–1957.
116. 116 Magnussen, H., Disse, B., Rodriguez-Roisin, R., Kirsten, A., Watz, H., Tetzlaff, K., et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 37 (2014), 1285–1294.
117. 117 Barnes, P.J., Chowdhury, B., Kharitonov, S.A., Magnussen, H., Page, C.P., Postma, D., et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174 (2006), 6–14.
118. 118 Rennard, S.I., Calverley, P.M., Goehring, U.M., Bredenbroker, D., Martinez, F.J., Reduction of exacerbations by the PDE4 inhibitor roflumilast—the importance of defining different subsets of patients with COPD. Respir Res, 12, 2011, 18.